NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Unconfirmed

**Date:** Wednesday 14 February and Wednesday 21 February 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair) Present for all items
2. Emtiyaz Chowdhury Present for all items
3. Sarah Davis Present for all items
4. Carrie Gardner Present for all items
5. Tina Garvey Present for all items
6. Professor Jonathan Ives Present 1 to 5.2.1
7. Dr Bernard Khoo Items 1 to 4.3.2
8. Philip Mallender Present for all items
9. Stuart Mealing Items 1 to 4.3.2
10. Carole Pitkeathley Present for all items
11. Angharad Shambler Present for all items

NICE staff (key players) present

Helen Knight, Director of Medicines Evaluation Items 4.2 to 4.3.1

Jacoline Bouvy, Programme Director - Medicines Evaluation Present for all items

Jasdeep Hayre, Associate Director Present for all items

Celia Mayers, Project Manager Present for all items

Claire Hawksworth, Health Technology Assessment Adviser Items 1 to 4.3.2

Owen Swales, Health Technology Assessment Analyst Items 5 to 5.2.1

Alan Moore, Health Technology Assessment Adviser Present for all items

Cara Gibbons, Health Technology Assessment Analyst Items 5 to 5.3.3

External assessment group representatives present

Mark Corbett, Centre for Reviews and Dissemination and Centre for Health Economics – York, Items 1 to 4.2.1

Robert Hodgson, Centre for Reviews and Dissemination and Centre for Health Economics – York, Items 1 to 4.2.1

Peter Auguste, Warwick Evidence, Items 5 to 5.3.1

Emanuela Castelnuovo, Warwick Evidence, Items 5 to 5.3.1

Clinical, Patient & NHS England experts present

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, Present for all items.

Ben Carpenter, Consultant Haematologist, clinical expert, nominated by Vertex Pharmaceuticals Ltd, Items 1 to 4.2.1

Clare Samuelson, Consultant Haematologist, clinical expert, nominated by UK Thalassaemia Society, Items 1 to 4.2.1

Subarna Chakravorty, Consultant Paediatric Haematologist, clinical expert, nominated by NHS England, Items 1 to 4.2.1

Gabriel Theophanous, Patient expert, nominated by UK Thalassaemia Society, Items 1 to 4.2.1

Roanna Maharaj, Patient expert, nominated by UK Thalassaemia Society, Items 1 to 4.2.1

Emma Drasar, Consultant Haematologist – clinical expert, nominated by Anthony Nolan, Items 1 to 4.2.1 & 5 to 5.2.1

Josh Wright, Consultant Haematologist, clinical expert, nominated by Anthony Nolan, Items 5 to 5.2.1

Funmi Dasaolu, Patient expert, nominated by Anthony Nolan & Sickle Cell Society, Items 5 to 5.2.1

Toby Bakare, Patient expert, nominated by Anthony Nolan & Sickle Cell Society, Items 5 to 5.2.1

Observers present

Dr Iolo Doull, Incoming HST Evaluation Committee Vice-Chair, Items 1 to 4.3.2 & 5 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair Dr Paul Arundel welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Annett Blochberger, Sara Payne, Professor Ed Wilson, Dr Shehla Mohammed, and Anthony Williams.

### News and announcements

* 1. The chair introduced and welcomed Dr Iolo Doull who will be observing this meeting before starting his role on the committee as Vice Chair in March 2024.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 10 January 2024.

### Appraisal of exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Vertex Pharmaceuticals.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11250).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Bernard Khoo, Carole Pitkeathley and Philip Mallender.
  2. Part 2a – Closed session (members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  3. Part 2b – Closed session (company representatives, clinical and patient experts, and external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11250>

### Appraisal of exagamglogene autotemcel for treating sickle cell disease [ID4016]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Vertex Pharmaceuticals.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11249).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Angharad Shambler, Carole Pitkeathley, and Philip Mallender.

Due to the complex and lengthy discussions that took place for the first topic ID4015; NICE key players, Committee members, Company representatives and experts all agreed that to give this appraisal the time and consideration needed we would have to put a hold on discussions for this appraisal. The NICE team agreed to schedule an additional meeting cover Part 2a and Part 2b on Wednesday 21 February 2024.

* 1. Part 2a – Closed session (member of this public were not present for this section of the meeting.)
     1. The committee began discussions on the confidential information submitted for this item.
  2. Part 2b - Closed session (company representatives, clinical and patient experts were asked to leave the meeting)
     1. External assessment group representatives then left the meeting after a brief discussion with the committee members.
     2. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11249>

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Thursday 7 March 2024 and will start promptly at 9am.